New data boost Novartis program to market biosimilar of Humira

14 September 2017

Sandoz, the generic medicines unit of Swiss drug major Novartis (NOV: N), has released new data bolstering its case for regulatory approval for its biosimilar adalimumab.

The one-year study comparing the biosimilar with its reference biologic Humira (adalimumab), from AbbVie (NYSE: ABBV), showed that efficacy and safety profiles in moderate-to-severe chronic plaque psoriasis were comparable.

Results were presented at the 26th Congress of the European Academy of Dermatology and Venereology in Geneva, Switzerland.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK